The overexpression of c-Met and/or its correlation with poor prognosis has been reported in various human malignancies, including lung cancer [5, 6], breast cancer [7, 8], head and neck cancer [9–11], gastric cancer [12–14], colorectal cancer [15], bladder cancer [16], uterine cervix carcinoma [17], and esophageal adenocarcinoma [18]. The gene discussed is MET; the disease is gastric cancer.